Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Trulicity ® (dulaglutid) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
A phase 3, double-blind, 28-week study (AWARD-9) evaluated the efficacy and safety of once-weekly dulaglutide 1.5 mg administered SC compared with once-weekly placebo when both were added to titrated daily IGlar with or without metformin in patients with T2DM.1
Treatment with dulaglutide 1.5 mg
was superior to treatment with placebo in mean change in HbA1c from baseline to 28 weeks (p<.001)
resulted in significantly greater reductions in mean FSG and mean BW from baseline to 28 weeks compared with placebo (p<.001), and
produced more patients that reached a HbA1c target of less than 7% or less than or equal to 6.5% from baseline, compared with placebo (p<.001) (Table 1).1
Table 1. Efficacy Parameters at Week 28 in AWARD-91
|
Parameter |
Dulaglutide 1.5 mg (n=150a) |
Placebo (n=150a) |
Treatment Difference |
|
ΔHbA1cb, % |
-1.44±0.09 |
-0.67±0.09 |
-0.77±0.10c |
|
ΔFSGb, mmol/L (mg/dL) |
-2.48± 0.26 (-44.63±4.16) |
-1.69 ± 0.26 (-27.90±4.08) |
-1.05± 0.30 (-16.73±4.72)c |
|
ΔBWb, kg |
-1.91±0.30 |
+0.50±0.30 |
-2.41±0.39c |
|
HbA1c <7%, % of patients |
66.7c |
33.3 |
--- |
|
HbA1c ≤6.5%, % of patients |
50.0c |
16.7 |
--- |
Abbreviations: Δ = change from baseline; AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; BW = body weight; FSG = fasting serum glucose; HbA1c = glycated hemoglobin.
a Intent-to-treat population.
b Least-squares mean ± SE.
c p<.001, dulaglutide 1.5 mg vs placebo.
Increases in the mean IGlar dose were significantly smaller in the dulaglutide treatment group, 13±2 units, compared to the placebo group, 26±2 units, at 28 weeks (p<.001).1
The most frequent reasons for discontinuation were patient decision (dulaglutide 1.5 mg, n=3; placebo, n=7) and AE (dulaglutide 1.5 mg, n=6; placebo, n=2).1
TEAEs were reported in significantly more patients who received dulaglutide 1.5 mg, 64%, compared with patients who received placebo, 50% (p=.014).1
The most common TEAEs were GI in nature, and hypoglycemia TEAEs were similar between treatment groups.1
Information from the label
Patients receiving dulaglutide in combination with sulphonylurea or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia may be lowered by a reduction in the dose of sulphonylurea or insulin.2
1. Pozzilli P, Norwood P, Jódar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024-1031. http://dx.doi.org/10.1111/dom.12937
2. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
AE = adverse event
AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes
BW = body weight
FSG = fasting serum glucose
GI = gastrointestinal
HbA1c = glycated hemoglobin
IGlar = insulin glargine
SC = subcutaneous
T2DM = type 2 diabetes mellitus
TEAE = treatment-emergent adverse event
Datum fӧr senaste ӧversyn 2019 M08 24